Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: Evaluation of TOP2A, HER-2/neu, and survivin

Annals of Surgical Oncology

Volumn 19, Issue 6, 2012, Pages 1790-1799

  Da Cunha, Isabela Werneck ^a   De Brot, Louise ^a   Carvalho, Kátia Cândido ^a,b   Rocha, Rafael Malagoli ^a   Fregnani, José Humberto ^a,c   Falzoni, Roberto ^a,b   De Oliveira Ferreira, Fábio ^a   Junior, Samuel Aguiar ^a   Lopes, Ademar ^a   Muto, Nair Hideko ^a   Reis, Luiz F L ^a,d   Soares, Fernando Augusto ^a   Vassallo, José ^a,e  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d HOSPITAL SÍRIO LIBANÊS   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SURVIVIN; TOPOISOMERASE 2 ALPHA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALVEOLAR SOFT PART SARCOMA; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 17Q; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FIBROMATOSIS; FIBROSARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MYXOFIBROSARCOMA; OUTCOME ASSESSMENT; SOFT TISSUE SARCOMA; SYNOVIAL BURSA; TISSUE MICROARRAY; TUMOR VOLUME; UNDIFFRENTIATED PLEOMORPHIC SARCOMA;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; FIBROMA; FIBROMATOSIS, AGGRESSIVE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; SARCOMA; SARCOMA, SYNOVIAL; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84865119650     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2184-3     Document Type: Article

References (52)

1. Lahat G, Tuvin D, Wei C, et al. New perspectives for staging and prognosis of soft tissue sarcoma. Ann Surg Oncol. 2008;15:2739-48.
2. Thway K. Pathology of soft tissue sarcomas. Clin Oncol. 2009;21:695-705.
3. Segal NH, Pavlidis P, Antonescu CR, et al. Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am J Pathol. 2003;163:691-700.
4. Tschoep K, Kohlmann A, Schlemmer M, et al. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol. 2007;63:111-24. (Pubitemid 46990915)
5. Skubitz KM, Pambuccian S, Manivel JC, et al. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med. 2008;6:23.
6. Cunha IW, Carvalho KC, Martins WK, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol. 2010;3:23-32.
7. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol. 1993;4:533-43. (Pubitemid 23257550)
8. Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105:9053-8.
9. Pritchard KI, Messersmith H, Elavathil L, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. 2008;26:736-44. (Pubitemid 351264386)
10. Esteva FJ, Hortobagyi GN. Topoisomerase IIa amplification and anthacycline-based chemotherapy: the jury is still out. J Clin Oncol. 2009;27:3416-7.
11. Järvinen TAH, Liu ET. Topoisomerase IIa gene (TOP2A) amplification and deletion in cancer-more common than anticipated. Cytopathology. 2003;14:309-13. (Pubitemid 37521860)
12. Järvinen TAH, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000;156:839-47. (Pubitemid 30626942)
13. Di Leo A, Isola J. Topoisomerase IIa as a marker predicting the efficacy of anthacyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer. 2003;4:179-86. (Pubitemid 37185053)
14. Arriola E, Marchio C, Tan DSP, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest. 2008;88:491-503. (Pubitemid 351581454)
15. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009;101:644-50.
16. Pritchard KI. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthacycline-based adjuvant chemotherapy for breast cancer? J Clin Oncol. 2009;24:3875-6.
17. Kanta SY, Yamane T, Dobashi Y, et al. Topoisomerase IIa gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006;37: 1333-43. (Pubitemid 44380283)
18. Tretiakova M, Turkyilmaz M, Grushko T, et al. Topoisomerase IIa in Wilm's tumour: gene alterations and immunoexpression. J Clin Pathol. 2006;59:1272-7. (Pubitemid 46048331)
19. Al-Kuraya K, Novotny H, Bavi P, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007;60:768-72. (Pubitemid 47056905)
20. Dimov ND, Zynger DL, Luan C, et al. Topoisomerase II alpha expression in testicular germ cell tumors. Urology. 2007;69: 955-61. (Pubitemid 46670241)
21. Mano MS, Rosa DD, De Azambuja E, et al. The 17q12-q21 amplicon: Her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev. 2007;33:64-77. (Pubitemid 46132005)
22. Murphy AJ, Hughes CA, Barrett C, et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007;67:2893-8. (Pubitemid 46548980)
23. Berney DM, Stankiewicz E, Adlan AMA, et al. DNA topoiso-merase I and IIa expression in penile carcinomas: assessing potential tumour chemosensitivity. BJU Int. 2008;102:1040-4.
24. Ferrandina G, Petrillo M, Carbone A, et al. Prognostic role of topoisomerase-IIa in advanced ovarian cancer patients. Br J Cancer. 2008;98:1910-5. (Pubitemid 351821572)
25. Liang Z, Zeng X, Gao I, et al. Analysis of EGFR, HER2 and TOP2A gene status and chomosomal polysomy in gastric ade-nocarcinoma from Chinese patients. BMC Cancer. 2008;8:23.
26. Washiro M, Ohtsuka M, Kimura F, et al. Upregulation of topo-isomerase IIa expression in advanced gallbladder carcinoma: a potential chemotherapeutic target. J Cancer Res Clin Oncol. 2008;134:793-801.
27. Baiocchi GL, Villanacci V, Rossi E, et al. HER-1/Neu and topoisomerase-IIa expression and genic amplification in pancreatic adenocarcinoma. Dig Dis Sci. 2009;54:2049-51.
28. Coss A, Tosetto M, Fox EJ, et al. Increased topoisomerase IIa expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett. 2009;276:228-38.
29. Maruya S, Shirasaki T, Nagaki T, et al. Differential expression of topoisomerase IIa protein in salivary gland carcinomas: histoge-netic and prognostic implications. BMC Cancer. 2009;9:72.
30. Tsavaris N, Lazaris A, Kosmas C, et al. Topoisomerase I and IIa protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. Cancer Chemother Pharmacol. 2009;64:391-8.
31. Wong N, Yeo W, Wong WL, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer. 2009;124:644-52.
32. Skotheim RI, Kallioniemi A, Bjerkhagen B, et al. Topoisomer-ase-IIa is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol. 2003;21:4586-91. (Pubitemid 46594031)
33. Storlazzi CT, Brekke h, Mandahl N, et al. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol. 2006;209:492-500. (Pubitemid 44194564)
34. Lévy P, Vidaud D, Leroy K, et al. Molecular profiling of malignant peripheral nerve sheath tumors associated with neu-rofibromatosis type I, based on large-scale real-time RT-PCR. Mol Cancer. 2004;3:20.
35. Rudolph P, Kellner U, Chassevent A, et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft tissue sarcoma. A multivariate study. Am J Pathol. 1997;150:1997-2007. (Pubitemid 27233073)
36. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22:8581-9. (Pubitemid 38019195)
37. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709-14.
38. Kappler M, Kotzsch M, Bartel F, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res. 2003;9:1098-104. (Pubitemid 36323717)
39. Taubert H, Heidenreich C, Holzhausen HJ, et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 2010;10:65.
40. Yaziji H, Taylor C. Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 testing. Appl Immunohistochem Mol Morphol. 2007;15:239-41. (Pubitemid 47329912)
41. Bhargawa R, Lal P, Chen B. HER-2/neu and topoisomerse IIa gene amplification and protein expression in invasive breast carcinomas. Chomogenic in situ hybridization and immunohis-tochemical analyses. Am J Clin Pathol. 2005;123:889-95. (Pubitemid 40740688)
42. Durbecq V, Desmed C, Paesmans M, et al. Correlation between topoisomerase-II-alpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004;25:1473-9.
43. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chomo-somes Cancer. 2004;39:288-97. (Pubitemid 38326310)
44. Gaumann A, Tews DS, Mentzel T, et al. Expression of drug resistance related protein in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. Virchows Arch. 2003;442:529-37. (Pubitemid 36819246)
45. Nuciforo PG, Pellegrini C, Fasani R, et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol. 2003;34:639-45. (Pubitemid 36875508)
46. Thomas DG, Giordano TJ, Sanders D, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005;103:830-8. (Pubitemid 40216413)
47. Caldas H, Holloway MP, Hall BM, et al. Survivin-directed RNA interference cocktail is a potent suppressor of tumor growth in vivo. J Med Genet. 2006;43:119-28. (Pubitemid 43262965)
48. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133-9. (Pubitemid 47062670)
49. Kappler M, Köhler T, Kampf C, et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer (Pred Oncol). 2001;95:360-3. (Pubitemid 33015105)
50. Würl P, Kappler M, Meye A, et al. Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet. 2002;359:943-5. (Pubitemid 34246386)
51. Kappler M, Bache M, Bartel F, et al. Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independent of p53. Cancer Gene Ther. 2004;11:186-93. (Pubitemid 38280521)
52. Taubert H, Kappler M, Bache M, et al. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcoma patients. Oncogene. 2005;24:5258-61. (Pubitemid 41192443)